Dr. Brose Discusses Lenvatinib for the Treatment of Patients With Thyroid Cancer
Marcia S. Brose, MD, PhD, discusses the SELECT trial, which looks at lenvatinib for patients with 131I-refractory differentiated thyroid cancer.
Lenvatinib has been a very active agent both in the first-line setting and in patients previously treated with other agents, including ceritinib, says Brose.
In both cases, patients treated with lenvatinib are doing well and the response rate is very high. In a phase III trial, 63% of patients experienced a partial response, and a couple of complete responses were also reported.
Brose believes this is clinically significant, especially when patients have very aggressive or symptomatic disease.
Marcia S. Brose, MD, PhD, associate professor of Otorhinolaryngology, Head and Neck Surgery at the Hospital of the University of Pennsylvania, discusses the SELECT trial, which looks at lenvatinib for patients with131I-refractory differentiated thyroid cancer.
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
Anticipating Novel Options for the RAI-Refractory DTC Armamentarium
May 15th 2023In season 4, episode 6 of Targeted Talks, Warren Swegal, MD, takes a multidisciplinary look at the RAI-refractory differentiated thyroid cancer treatment landscape, including the research behind 2 promising systemic therapy options.
Listen
AI-Driven Deep Learning Model Shows Promise in Standardizing MDS Diagnosis
December 10th 2024In an interview, Palak Dave discussed how artificial intelligence, using deep learning to analyze bone marrow aspirate smear images, could standardize and accelerate the diagnosis of MDS vs pre-MDS conditions.
Read More
Systemic Therapy Choice Linked to Radiosurgery Outcomes in Brain Mets
December 6th 2024In an interview with Targeted OncologyT, Rupesh Kotecha, MD, discussed a study focused on how systemic therapy selection impacts outcomes in patients with brain metastases, particularly those with lung cancer.
Read More
Post Hoc and Real-World Analyses Explore Benefit of Lenvatinib in DTC
December 5th 2024During a Case-Based Roundtable® event, Lori J. Wirth, discussed recent analyses that have developed a better understanding of the outcomes with lenvatinib in differentiated thyroid cancer in the second article of a 2-part series.
Read More
